NL-OMON24984尚未招募不适用
Maraviroc Immune Recovery Study.
MC Utrecht0 个研究点目标入组 130 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 130
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age 18 years or older;
- •2. HAART with a maximal treatment interruption of two weeks;
排除标准
- •1. HAART consisting of a combination of tenofovir and didanosine;
- •2. Active infection for which antimicrobial treatment;
研究者
相似试验
已完成
4 期
Maraviroc Immune Recovery Study (MIRS): A multicentre, randomized, placebo-controlled, exploratory mechanistic study into the role of Maraviroc on immune recoveryHIVhuman immunodeficiency virus10047438NL-OMON35447niversitair Medisch Centrum Utrecht130
进行中（未招募）
不适用
Maraviroc Immune Recovery Study (MIRS):A multicentre, randomized, placebo-controlled, exploratory mechanistic study into the role of Maraviroc on immune recovery - MIRSEUCTR2008-003635-20-NLniversitair Medisch Centrum Utrecht
已完成
4 期
Maraviroc Immune Recovery StudyHIV InfectionsNCT00875368S.F.L. van Lelyveld85
进行中（未招募）
不适用
Efecto del maraviroc (MVC) en la recuperación inmunológica de pacientes infectados por el VIH-1 con respuesta discordante y una cifra de linfocitos CD4 inferior a las 200 células/mm3Pacientes con infección por VIHMedDRA version: 9Level: LLTClassification code 10020172Term: HIV infection NOSEUCTR2009-012543-42-ESFundació Clínic
进行中（未招募）
不适用
se of Maraviroc (MVC) in immunogical non-responder HIV-1-infected patients. - NDHIV-1-infected HAART-treated patients that reached a virologic suppression without a reconstitution of their immune system.MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2008-002661-30-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)